“A consistent trend of higher ocrelizumab exposure leading to greater reduction in risk of confirmed disability progression was observed, particularly in the relapsing MS trials, and was not associated with a higher rate of adverse events,”...
“A consistent trend of higher ocrelizumab exposure leading to greater reduction in risk of confirmed disability progression was observed, particularly in the relapsing MS trials, and was not associated with a higher rate of adverse events,”...
“A consistent trend of higher...